ASH1L and neoplasm: To investigate the potential of targeting ASH1L as a clinical intervention, we evaluated AS‐99, a recently developed small molecule inhibitor of the ASH1L, on tumor cells and HSCs.[22] Upon treatment with AS‐99, the expression of HSC activation marker genes and profibrogenic genes decreased in LX2 HSCs (Figure S8A, Supporting Information), which was consistent with the results of ASH1L knockdown.